A Summary of Viral Targets and Recently Released PDB IDs of SARS-CoV-2
Rohit Bhatia1, *, Raj K. Narang1, Ravindra K. Rawal2
Identifiers and Pagination:Year: 2020
First Page: 7
Last Page: 8
Publisher Id: TOVJ-14-7
Article History:Electronic publication date: 16/04/2020
Collection year: 2020
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Drug discovery and development against coronavirus disease 2019 (COVID-19) is the utmost need and the most challenging task of the hour. Many research groups from different countries are working continuously in this direction, and till 8th March 2020, a total of 382 clinical trials have been registered on the WHO’s International Clinical Trials Registry Platform . There is an urgent need to identify specific targets to design promising therapeutic agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. Analysis of SARS-CoV-2 reveals seven major target proteins that can be considered for drug design against the virus. These include the spike, envelope, membrane, nucleocapsid, protease, hemagglutinin esterase and helicase [2, 3]. Beyond these, several Non Structural Proteins (NSPs) can also be evaluated as targets for drug development . There are only a few Protein Data Bank (PDB) Ids available related to SARS-CoV-2 in the RCSB database. Table 1 summarizes recently released PDB Ids (from 5.2.2020 to 25.3.2020) for various SARS-CoV-2 targets .
The SARS-CoV-2 genome encodes a relatively large number of proteins . The PL proteinase and the 3CL protease cleave two polyproteins to release different types of NSPs. Hence the proteases represent a relevant target for designing drugs against SARS-CoV-2. The spike (S) protein helps the virus to enter inside the host and also activates the immune response of the host against the virus through the interaction mediated by its specific segments . Thus, the S protein represents an ideal target for therapeutic drug development. The envelope protein is the smallest protein of SARS-CoV-2 and plays a significant role in morphogenesis of virus particles . It is also reported that the oligomerization of these proteins leads to the formation of specific ion-channels whose role is still unclear. Beyond this, the envelop protein helps in viral assembly and budding, hence its significant as a drug target . Membrane proteins maintain the shape of a viral envelope  and also sensitize the host against the virus . These proteins can also be considered as significant targets for drug development. The nucleocapsid proteins have a structure comprising arm, central linker and tail domains . The main function of these proteins is to form ribonucleoprotein complexes. It also regulates replication, transcription of viral RNA and in the host cells, inhibits protein translation leading to disruption in the host cell metabolism [13, 14]. Therefore, targeting this protein can lead to blockbuster therapeutic agents for COVID-19 treatment. Hemagglutinin esterase has been established as a marker for the evolution of SARS-CoV-2 or some influenza infections and has the capacity to act as lectins or receptor destroying enzymes . The Helicase enzyme is also an interesting target, but its inhibitors are associated with some toxicity and specificity issues .
COVID-19 pandemic has now become a destructive ailment globally. Therefore the utmost need of the hour is to develop therapeutic candidates or vaccines against it. The targets explained in this summary may be of some aid to design novel molecules by employing drug discovery strategies such as artificial intelligence or CADD tools.
|Target||PDB Ids||Release Date||Web Links|
|Protease||5RE4, 5RE5, 5RE6, 5RE7, 5RE8, 5RE9, 5REA, 5REB, 5REC, 5RED, 5REE, 5REF, 5REG, 5REH, 5REI, 5REJ, 5REK, 5REL, 5REM, 5REN, 5REO, 5REP, 5RER, 5RES, 5RET, 5REU, 5REV, 5REW, 5REX, 5REY, 5REZ, 5RF0, 5RF1, 5RF2, 5RF3, 5RF4, 5RF5, 5RF6, 5RF7, 5RF8, 5RF9, 5RFA, 5RFB, 5RFC, 5RFD, 5RFE, 5RFF, 5RFG, 5RFH, 5RFI, 5RFJ, 5RFK, 5RFL, 5RFM, 5RFN, 5RFO, 5RFP, 5RFQ, 5RFR, 5RFS, 5RFT, 5RFU, 5RFV, 5RFW, 5RFX, 5RFY, 5RFZ, 5RG0, 6W63||25.03.2020||
(Same link for all, just change the code of ID)
|6M17, 6VW1||11.3.2020, 4.3.2020||https://www.rcsb.org/structure/6M17, https://www.rcsb.org/structure/6VW1|
|Spike glycoprotein||6LXT, 6VSB||26.2.2020||https://www.rcsb.org/structure/6LXT, https://www.rcsb.org/structure/6VSB|
|Non structural polyprotein (NSP)||6LU7, 6M03||5.2.2020, 11.3.2020||https://www.rcsb.org/structure/6LU7, https://www.rcsb.org/structure/6M03|
|SARS CoV Protease with unliganded active site||6Y84, 6YB7||11.3.2020, 25.3.2020||https://www.rcsb.org/structure/6Y84, https://www.rcsb.org/structure/6YB7|
|COVID-19 protease in complex with Z1367324110||5R7Z, 5R80, 5R81, 5R82, 5R83, 5R84||11.3.2020||https://www.rcsb.org/structure/5R7Z, https://www.rcsb.org/structure/5R81, https://www.rcsb.org/structure/5R82, https://www.rcsb.org/structure/5R83, https://www.rcsb.org/structure/5R84|
CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
|||Oxford COVID-19 Evidence Service. https://www.cebm.net/covid-19 /registered-trials-and-analysis|
|||Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020; 52(1): 56-65.
|||Hilgenfeld R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014; 281(18): 4085-96.
|||Wang H, Xue S, Yang H, Chen C. Recent progress in the discovery of inhibitors targeting coronavirus proteases. Virol Sin 2016; 31(1): 24-30.
|||Protein Data Bank. www.rcsb.org|
|||Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 2020; 35(1): 145-51.
|||Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3(1): 237-61.
|||Kuo L, Hurst KR, Masters PS. Exceptional flexibility in the sequence requirements for coronavirus small envelope protein function. J Virol 2007; 81(5): 2249-62.
|||Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. Coronavirus envelope (E) protein remains at the site of assembly. Virology 2015; 478: 75-85.
|||Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16(1): 69.
|||Wang Y, Liu L. The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogen-associated molecular pattern to promote beta interferon induction via a toll-like-receptor-related TRAF3-independent mechanism. MBio 2016; 7(1): e01872-15.
|||Chang CK, Lo SC, Wang YS, Hou MH. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today 2016; 21(4): 562-72.
|||J Alsaadi EA, Jones IM. Membrane binding proteins of coronaviruses. Future Virol 2019; 14(4): 275-86.
|||Zhou B, Liu J, Wang Q, et al. The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1alpha. J Virol 2008; 82(14): 6962-71.
|||Zeng Q, Langereis MA, van Vliet AL, Huizinga EG, de Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci USA 2008; 105(26): 9065-9.
|||Frick DN, Lam AM. Understanding helicases as a means of virus control. Curr Pharm Des 2006; 12(11): 1315-38.